| Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... New England Journal of Medicine 385 (12), 1091-1103, 2021 | 1944 | 2021 |
| Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms EA Sausville, SG Arbuck, R Messmann, D Headlee, KS Bauer, RM Lush, ... Journal of Clinical Oncology 19 (8), 2319-2333, 2001 | 391 | 2001 |
| PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum … RW Naumann, RL Coleman, RA Burger, EA Sausville, E Kutarska, ... Journal of clinical oncology 31 (35), 4400-4406, 2013 | 231 | 2013 |
| Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor–positive solid tumors RE Fisher, BA Siegel, SL Edell, NM Oyesiku, DE Morgenstern, ... Journal of Nuclear Medicine 49 (6), 899-906, 2008 | 181 | 2008 |
| A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19 (+), CD22 (+ … RA Messmann, ES Vitetta, D Headlee, AM Senderowicz, WD Figg, ... Clinical Cancer Research 6 (4), 1302-1313, 2000 | 167 | 2000 |
| Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms AR Tan, D Headlee, R Messmann, EA Sausville, SG Arbuck, AJ Murgo, ... Journal of clinical oncology 20 (19), 4074-4082, 2002 | 156 | 2002 |
| Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic F Shah, D Logsdon, RA Messmann, JC Fehrenbacher, ML Fishel, ... NPJ precision oncology 1 (1), 19, 2017 | 138 | 2017 |
| Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors PM LoRusso, MJ Edelman, SL Bever, KM Forman, MJ Pilat, MF Quinn, ... Journal of clinical oncology 30 (32), 4011-4016, 2012 | 125 | 2012 |
| A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors AW Tolcher, WV Rodrigueza, DW Rasco, A Patnaik, KP Papadopoulos, ... Cancer chemotherapy and pharmacology 73, 363-371, 2014 | 113 | 2014 |
| Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). MJ Morris, JS De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ... Journal of Clinical Oncology 39 (18_suppl), LBA4-LBA4, 2021 | 111 | 2021 |
| Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials RL Van Heertum, R Scarimbolo, JG Wolodzko, B Klencke, R Messmann, ... Drug design, development and therapy, 1719-1728, 2017 | 107 | 2017 |
| The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease RA Caston, S Gampala, L Armstrong, RA Messmann, ML Fishel, ... Drug Discovery Today 26 (1), 218-228, 2021 | 90 | 2021 |
| Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan™ EL Matteson, VJ Lowe, FG Prendergast, CS Crowson, KG Moder, ... Clinical and experimental rheumatology 27 (2), 253, 2009 | 84 | 2009 |
| Clinical Pharmacokinetics and Exposure‐Toxicity Relationship of a Folate‐Vinca Alkaloid Conjugate EC145 in Cancer Patients J Li, EA Sausville, PJ Klein, D Morgenstern, CP Leamon, RA Messmann, ... The Journal of Clinical Pharmacology 49 (12), 1467-1476, 2009 | 81 | 2009 |
| The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin’s lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of … J Schindler, E Sausville, R Messmann, JW Uhr, ES Vitetta Clinical cancer research 7 (2), 255-258, 2001 | 73 | 2001 |
| Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications CP Leamon, JA Reddy, PJ Klein, IR Vlahov, R Dorton, A Bloomfield, ... The Journal of pharmacology and experimental therapeutics 336 (2), 336-343, 2011 | 66 | 2011 |
| Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant … K Fizazi, K Herrmann, BJ Krause, K Rahbar, KN Chi, MJ Morris, O Sartor, ... The Lancet Oncology 24 (6), 597-610, 2023 | 61 | 2023 |
| VISION investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... N Engl J Med 385 (12), 1091-1103, 2021 | 49 | 2021 |
| Mechanical properties of sickle cell membranes R Messmann, S Gannon, S Sarnaik, RM Johnson | 45 | 1990 |
| Why we did what we did: PSMA PET/CT selection criteria for the VISION trial PH Kuo, T Benson, R Messmann, M Groaning Journal of Nuclear Medicine 63 (6), 816-818, 2022 | 44 | 2022 |
